Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1—Infected Patients With High-Level Viral Load: Preliminary Data From the Real World

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy–naive adults with HIV-1 infection

(2021) Pedro Cahn et al.   AIDS

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1

(2021) Itzchak Levy et al.   CLINICAL MICROBIOLOGY AND INFECTION

Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine

(2020) Joseph Eron et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Optimizing Treatment for Adults with HIV/AIDS in China: Successes over Two Decades and Remaining Challenges

(2020) Wei Cao et al.   Current HIV/AIDS Reports

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2020) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

“Late for testing, early for antiretroviral therapy, less likely to die”: results from a large HIV cohort study in China, 2006–2014

(2018) Houlin Tang et al.   BMC INFECTIOUS DISEASES

Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients

(2018) Barbara Rossetti et al.   EXPERT OPINION ON PHARMACOTHERAPY

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

(2018) Pedro Cahn et al.   LANCET

Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study

(2017) Pedro Cahn et al.   Journal of the International AIDS Society

Dual antiretroviral therapy: finding a place in the battle

(2016) Daniel Podzamczer et al.   Lancet HIV